Log in

NASDAQ:SELB - Selecta Biosciences Stock Price, Forecast & News

-0.05 (-1.17 %)
(As of 02/21/2020 04:00 PM ET)
Today's Range
Now: $4.22
50-Day Range
MA: $3.49
52-Week Range
Now: $4.22
Volume348,910 shs
Average Volume735,328 shs
Market Capitalization$158.80 million
P/E RatioN/A
Dividend YieldN/A
Selecta Biosciences, Inc, a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its proprietary pipeline includes therapeutic enzymes, gene therapies, and other products and product candidates affected by undesired immune responses. The company's lead product is SEL-212 that in Phase II clinical trials for the treatment of chronic refractory gout. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:SELB



Sales & Book Value

Annual Sales$900,000.00
Book Value($0.24) per share


Net Income$-65,340,000.00


Market Cap$158.80 million
Next Earnings Date3/20/2020 (Estimated)

Receive SELB News and Ratings via Email

Sign-up to receive the latest news and ratings for SELB and its competitors with MarketBeat's FREE daily newsletter.

Selecta Biosciences (NASDAQ:SELB) Frequently Asked Questions

What is Selecta Biosciences' stock symbol?

Selecta Biosciences trades on the NASDAQ under the ticker symbol "SELB."

How were Selecta Biosciences' earnings last quarter?

Selecta Biosciences Inc (NASDAQ:SELB) posted its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.02. View Selecta Biosciences' Earnings History.

When is Selecta Biosciences' next earnings date?

Selecta Biosciences is scheduled to release their next quarterly earnings announcement on Friday, March 20th 2020. View Earnings Estimates for Selecta Biosciences.

What price target have analysts set for SELB?

6 analysts have issued twelve-month price objectives for Selecta Biosciences' shares. Their forecasts range from $6.00 to $13.00. On average, they anticipate Selecta Biosciences' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 113.3% from the stock's current price. View Analyst Price Targets for Selecta Biosciences.

What is the consensus analysts' recommendation for Selecta Biosciences?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Selecta Biosciences.

What are Wall Street analysts saying about Selecta Biosciences stock?

Here are some recent quotes from research analysts about Selecta Biosciences stock:
  • 1. According to Zacks Investment Research, "Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States. " (1/9/2020)
  • 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating after SELB reported its 2Q19 financial and business update. We are encouraged by the company’s announced partnership with AskBio to develop gene therapies leveraging SELB’s ImmTOR platform, which may allow for re- dosing, but could also confer benefits on first dosing as well. While the announcement is a nice positive, no upfront cash or non-dilutive financing was secured through the deal, something we would have liked to see given the company’s capital overhang, which is a growing concern. While the interim results of the COMPARE study, which are expected in 4Q19, remain the key event for the stock, the study’s design using Krystexxa as a monotherapy may not fully de-risk the program commercially in the eyes of investors though, we do think it will further de-risk SEL-212 from a safety/efficacy perspective and inform the Phase 3 study design." (8/9/2019)
  • 3. Mizuho analysts commented, "We believe these readouts will be key drivers for SELB shares in late 2019/early 2020." (5/10/2019)

Has Selecta Biosciences been receiving favorable news coverage?

Media headlines about SELB stock have trended somewhat positive on Saturday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Selecta Biosciences earned a daily sentiment score of 0.9 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Selecta Biosciences.

Are investors shorting Selecta Biosciences?

Selecta Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 629,000 shares, an increase of 14.8% from the January 15th total of 547,900 shares. Based on an average trading volume of 451,200 shares, the short-interest ratio is currently 1.4 days. Currently, 1.8% of the company's shares are short sold. View Selecta Biosciences' Current Options Chain.

Who are some of Selecta Biosciences' key competitors?

What other stocks do shareholders of Selecta Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include SCYNEXIS (SCYX), VBI Vaccines (VBIV), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Viking Therapeutics (VKTX) and Amarin (AMRN).

Who are Selecta Biosciences' key executives?

Selecta Biosciences' management team includes the folowing people:
  • Dr. Omid C. Farokhzad, Co-Founder, Chairman & Member of the Scientific Advisory Board (Age 50)
  • Dr. Lloyd Johnston, COO and Sr. VP of R&D (Age 51)
  • Dr. John H. Leaman, Exec. Officer (Age 46)
  • Dr. Werner Cautreels, Advisor (Age 67)
  • Dr. Carsten Brunn, CEO, Pres & Director (Age 48)

When did Selecta Biosciences IPO?

(SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel served as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers.

Who are Selecta Biosciences' major shareholders?

Selecta Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include EcoR1 Capital LLC (12.22%), BVF Inc. IL (8.73%), Boxer Capital LLC (8.73%), Renaissance Technologies LLC (2.32%), Man Group plc (2.29%) and Quantitative Systematic Strategies LLC (0.09%). Company insiders that own Selecta Biosciences stock include Amir Nashat, Carsten Brunn and Timothy C Barabe. View Institutional Ownership Trends for Selecta Biosciences.

Which major investors are selling Selecta Biosciences stock?

SELB stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Goldman Sachs Group Inc. and Bank of America Corp DE. View Insider Buying and Selling for Selecta Biosciences.

Which major investors are buying Selecta Biosciences stock?

SELB stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Boxer Capital LLC, BVF Inc. IL, Renaissance Technologies LLC, Quantitative Systematic Strategies LLC, Schonfeld Strategic Advisors LLC, Tower Research Capital LLC TRC and Stifel Financial Corp. Company insiders that have bought Selecta Biosciences stock in the last two years include Amir Nashat and Timothy C Barabe. View Insider Buying and Selling for Selecta Biosciences.

How do I buy shares of Selecta Biosciences?

Shares of SELB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Selecta Biosciences' stock price today?

One share of SELB stock can currently be purchased for approximately $4.22.

How big of a company is Selecta Biosciences?

Selecta Biosciences has a market capitalization of $158.80 million and generates $900,000.00 in revenue each year. The company earns $-65,340,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis. Selecta Biosciences employs 39 workers across the globe.View Additional Information About Selecta Biosciences.

What is Selecta Biosciences' official website?

The official website for Selecta Biosciences is http://www.selectabio.com/.

How can I contact Selecta Biosciences?

Selecta Biosciences' mailing address is 480 Arsenal Way, Watertown MA, 02472. The company can be reached via phone at 617-923-1400 or via email at [email protected]

MarketBeat Community Rating for Selecta Biosciences (NASDAQ SELB)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  256 (Vote Outperform)
Underperform Votes:  339 (Vote Underperform)
Total Votes:  595
MarketBeat's community ratings are surveys of what our community members think about Selecta Biosciences and other stocks. Vote "Outperform" if you believe SELB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SELB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel